Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
14 août 2023 08h00 HE
|
Clene Inc.
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8® in the HEALEY ALS Platform...
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
02 août 2023 07h00 HE
|
Clene Inc.
SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
26 juin 2023 08h00 HE
|
Clene Inc.
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-upSALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) --...
Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
21 juin 2023 09h20 HE
|
Clene Inc.
Investment led by Vivo Capital with participation from SymBiosis, Acuta Capital Partners, AIGH Capital, Serrado Capital LLC, and other new biotech investors, with support from existing insiders $40...
Clene Announces Pricing of $40 Million Public Offering
16 juin 2023 08h00 HE
|
Clene Inc.
SALT LAKE CITY, June 16, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Announces Launch of Proposed Public Offering
15 juin 2023 16h38 HE
|
Clene Inc.
SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
15 juin 2023 16h29 HE
|
Clene Inc.
CNM-Au8® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04)Clene plans to discuss the totality of the survival and...
Clene to Participate in the Maxim Group Virtual Healthcare Conference
15 juin 2023 07h00 HE
|
Clene Inc.
SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis
25 mai 2023 08h00 HE
|
Clene Inc.
SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights
12 mai 2023 16h00 HE
|
Clene Inc.
ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical SALT LAKE CITY, May 12, 2023 (GLOBE NEWSWIRE) -- Clene Inc....